LISATA THERAPEUTICS I

Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time

22 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics to Present at BIO CEO & Investor Conference

20 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme

17 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy

04 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics Announces Completion of Enrollment in Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma

12 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics to Present at NobleCon19 Investor Conference

28 Nov 2023 15:05:03 By Nasdaq GlobeNewswire

Lisata Therapeutics Announces Participation in Upcoming Conferences in November

09 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

Lisata Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

02 Nov 2023 15:05:01 By Nasdaq GlobeNewswire

Lisata Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on Thursday, November 2nd at 4:30 p.m. Eastern Time

26 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide

24 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics Announces European Medicines Agency Has Granted LSTA1 Orphan Drug Designation for the Treatment of Pancreatic Cancer 

17 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics Announces Participation in Upcoming Conferences in October

28 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics Announces Participation in InfoSec World 2023

20 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics Announces First Patient Treated in the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Advanced Solid Tumors

12 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics Announces Outcome of Interim Futility Analysis for its Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma

06 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics Announces Participation in Upcoming Conferences in September

05 Sep 2023 07:00:01 By Nasdaq GlobeNewswire

Lisata Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

14 Aug 2023 15:05:00 By Nasdaq GlobeNewswire

Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Malignant Glioma

08 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14 After Market Trading and to Host Conference Call on Tuesday, August 15 at 8:30 a.m. Eastern Time

07 Aug 2023 07:30:00 By Nasdaq GlobeNewswire

Lisata Therapeutics Announces Retirement of Dr. Erkki Ruoslahti from Board of Directors

11 Jul 2023 07:30:00 By Nasdaq GlobeNewswire